Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
about
Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
P2860
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@en
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@nl
type
label
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@en
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@nl
prefLabel
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@en
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@nl
P2093
P356
P1433
P1476
Idarubicin and intermediate-do ...... --results of a phase-II trial.
@en
P2093
Aulitzky W
Schneller F
Schumacher K
P304
P356
10.1007/S002770050447
P577
1998-11-01T00:00:00Z